10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

This trial was conducted to determine whether the reduction in microvascular risk and improved glycemic control that had been observed with medical therapy, as compared with conventional dietary treatment, in patients with newly diagnosed type 2 diabetes was sustained during 10 years of follow-up. Despite an early loss of glycemic differences, continued microvascular risk reduction and emergent risk reductions for myocardial infarction and death from any cause were observed. Despite an early loss of glycemic differences, continued microvascular risk reduction and emergent risk reductions for myocardial infarction and death from any cause were observed. The United Kingdom Prospective Diabetes Study (UKPDS), a randomized, prospective, multicenter trial, showed that intensive glucose therapy in patients with newly diagnosed type 2 diabetes mellitus was associated with a reduced risk of clinically evident microvascular complications and a nonsignificant reduction of 16% in the relative risk of myocardial infarction (P=0.052). 1 In patients whose body weight was more than 120% of their ideal weight 2 and who primarily received metformin, reductions in the risk of myocardial infarction of 39% (P=0.01) and of death from any cause of 36% (P=0.01) were observed. The results of the UKPDS, which were published in 1998, . . .